Advanced Search >

Risk Minimisation Materials

Renal and Bone Effects Risk Minimisation Material Tenofovir Disoproxil for Children and Adolescents with HIV-1

This brochure contains important advice on the management of potential renal and bone effects of tenofovir disoproxil in HIV-1 infected children and adolescents aged 2 to <18 years, and the dosing recommendations for tenofovir disoproxil in this population.

For Healthcare Professionals

This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies. Continue